Current Status and Progress of Radioligand Therapy in Advanced Malignant Tumors
10.3971/j.issn.1000-8578.2025.24.0971
- VernacularTitle:放射性配体疗法在晚期恶性肿瘤中的应用现状及进展
- Author:
Dasheng QIU
1
;
NAGARAJAH JAMES
2
;
Diansheng CUI
3
;
Shaozhong WEI
3
Author Information
1. Department of Radiology and Nuclear Medicine, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China.
2. Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen NB6511, Holland.
3. Department of Urology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China.
- Publication Type:SPECIALFEATURE
- Keywords:
Radioligand therapy;
Malignancy;
Advanced
- From:
Cancer Research on Prevention and Treatment
2025;52(2):110-117
- CountryChina
- Language:Chinese
-
Abstract:
In 1946, radioactive iodine 131 was first used for the treatment of differentiated thyroid cancer. However, the limitations of early nuclear medicine technology, the lack of specificity, the efficacy of nuclide therapy, and its adverse effects have limited its widespreadly clinical application. In recent years, scientists and clinicians have linked radioisotopes to targeted parts (tumor-specific small molecules, peptides, or antibodies) to develop safe and effective nuclear drugs. Ra-223, Lutathera (lutetium-177), and Pluvicto (177Lu-PSMA-617) have been successfully used in clinical treatment. Radioligand therapy has gradually shown good efficacy in different tumors. This paper focuses on the current situation of the application of therapeutic radioligand drugs in advanced malignant tumors and the latest research results and treatment strategies to achieve more accurate and personalized treatment methods, thereby to improve the curative effect, and reduce adverse reactions.
